Amarin Corp issued the following announcement on April 12.
An a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, is supporting the presentation of three accepted scientific presentations at the National Lipid Association (NLA) Scientific Sessions in Las Vegas, NV, April 26-29, 2018.
"Amarin is proud to be working with partners like Optum Healthcare, the NHANES database and other experts to better determine the prevalence and potential health impact of persistent high triglycerides," said Craig B. Granowitz, M.D., Ph.D., senior vice president and chief medical officer of Amarin. "As this medical condition impacts tens of millions of Americans, determining the scope and potential consequences of this clinical condition is important for setting national healthcare priorities."
Data to be presented include:
Prevalence and Predictors of Residual Hypertriglyceridemia According to Statin Use in US Adults
-- Wenjun Fan, Sephy Philip, Craig Granowitz, Peter P. Toth, Nathan D. Wong
Knowledge, Perceptions, and Patterns of "Fish Oil" Use in Cardiac Patients
-- Daniel E. Hilleman, Robyn Teply, Kathleen A. Packard
High Triglycerides and ASCVD Are Significant Predictors of Major CV Events and Increased Costs in Statin-Treated Patients: Real-World Analysis
-- Peter P. Toth, Craig Granowitz, Michael Hull, Sephy Philip
Original source: http://investor.amarincorp.com/releasedetail.cfm?ReleaseID=1063708